OSI Systems, Inc. — Form 10-Q Summary
Reporting period: Three months ended September 30, 2022, the first quarter of fiscal 2023. The filing compares results with the three months ended September 30, 2021, and reports unaudited U.S. GAAP financial statements. The company designs and manufactures specialized electronic systems and components across Security, Healthcare, and Optoelectronics and Manufacturing divisions.
Key Financial Metrics
| Metric | Q1 FY2022 | Q1 FY2023 | Change |
|---|---|---|---|
| Net revenues | $279.3 million | $268.1 million | Down 4.0% |
| Gross profit | $99.3 million | $87.5 million | Down 11.9% |
| Gross margin | 35.6% | 32.6% | Down 300 bps |
| Income from operations | $24.7 million | $18.3 million | Down 25.8% |
| Operating margin | 8.8% | 6.8% | Down approximately 200 bps |
| Net income | $19.1 million | $11.2 million | Down 41.0% |
| Diluted EPS | $1.04 | $0.65 | Down 37.5% |
| Cash flow from operations | $(11.0) million | $17.2 million | Improved by $28.3 million |
Revenue by Division
- Security: $145.0 million, down 3.0%; represented 54% of consolidated revenue.
- Healthcare: $43.6 million, down 13.8%; represented 16% of consolidated revenue.
- Optoelectronics and Manufacturing: $79.5 million of external revenue, up 0.4%; represented 30% of consolidated revenue.
Liquidity, Debt, and Balance Sheet
- Cash and cash equivalents were $54.0 million at September 30, 2022, down from $64.2 million at June 30, 2022. Approximately 86% was held by foreign subsidiaries and was subject to repatriation tax considerations.
- Total assets were $1.468 billion and total stockholders’ equity was $624.7 million at September 30, 2022.
- Debt included $215.0 million outstanding under the revolving credit facility and $150.0 million under the term loan. Letters of credit outstanding were $67.2 million, and $317.8 million remained available under the revolving facility.
- The company repurchased and cancelled the remaining $242.3 million of 1.25% convertible notes on September 1, 2022, using borrowings under its credit facility.
- The company stated that cash, available credit facilities, and expected operating cash flow should be sufficient for operational needs for the next 12 months and the foreseeable future.
Material Changes Versus the Prior Comparable Period
- Revenue declined $11.2 million, primarily due to lower Security and Healthcare sales. Reported sales were negatively affected by approximately 1.8% from foreign currency movements, principally the stronger U.S. dollar.
- Gross margin decreased due to unfavorable Security sales mix, higher component, freight, and travel costs, lower Healthcare revenue, and a greater relative contribution from the lower-margin Optoelectronics and Manufacturing division.
- Operating expenses decreased $5.5 million, including lower SG&A and restructuring, impairment, and other charges. Restructuring and other charges fell from $2.5 million to $1.2 million.
- Interest and other expense increased from $2.0 million to $3.4 million because of higher borrowing levels and interest rates following the convertible-note refinancing.
- The effective tax rate increased from 15.9% to 24.4%. The prior-year period included a $2.1 million discrete tax benefit related to equity compensation, compared with a $0.1 million benefit in the current period.
- Operating cash flow improved to $17.2 million, primarily from favorable changes in accounts payable, customer advances, deferred revenue, and other working capital items. Inventory increased to $361.9 million from $333.9 million at June 30, 2022.
- Cash used in financing activities was $13.9 million, reflecting debt refinancing activity, $17.3 million of share repurchases, and $11.1 million of taxes paid related to net share settlements.
Outlook, Risks, Contingencies, and Unusual Items
- The filing does not provide a specific quantitative revenue or earnings forecast. Management expects available cash, operating cash flow, and credit facilities to meet near-term liquidity needs.
- Remaining performance obligations were approximately $404.0 million at September 30, 2022; management expects approximately 55% to be recognized over the following 12 months.
- Key risks include COVID-19-related supply chain and labor disruptions, component shortages, freight constraints, inflation, rising interest rates, foreign currency volatility, government budget and procurement changes, and the Russia-Ukraine conflict.
- The company reported that research and development activities in Ukraine for the Healthcare division had been somewhat impacted and warned of potential cyber, supply chain, and macroeconomic effects from the conflict.
- The Security division may benefit from European Union explosive-detection compliance requirements, with the relevant Standard 3 deadline generally extended to March 2024, although certain larger airports have earlier installation dates.
- Capped acquisition-related contingent consideration had a maximum remaining potential payment of $51.2 million; the recorded fair-value liability was $25.9 million at September 30, 2022.
- The company disclosed environmental matters and ordinary-course legal proceedings for which no loss accrual was recorded because unfavorable outcomes were not considered probable and reasonably estimable. An adverse resolution could nevertheless be material.
- The company recorded $0.9 million of legal charges and $0.3 million of employee termination costs in restructuring and other charges during the quarter.
- An interest-rate swap with a $175 million notional amount was entered into during September 2022 and had a fair value of $3.5 million at quarter-end.
Important Facts for Investors to Verify
- Whether Security and Healthcare revenue weakness reflects temporary program timing and foreign exchange effects or a more persistent demand slowdown.
- Whether component, freight, labor, and other inflationary costs continue to pressure gross margins.
- The pace of inventory conversion and working-capital normalization, particularly given the $361.9 million inventory balance.
- Interest-rate exposure and compliance with financial covenants under the $750 million secured credit facility.
- The timing and amount of potential acquisition-related contingent payments, including the $51.2 million maximum remaining obligation.
- Potential effects of COVID-19, supply chain constraints, the Russia-Ukraine conflict, foreign exchange movements, and government procurement decisions on orders and revenue recognition.
- The sustainability of share repurchases while the company carries increased revolving and term-loan borrowings.